Tissue Factor Science
Iconic Therapeutics is leveraging its deep insight into the role of tissue factor in inflammation and angiogenesis to develop breakthrough medicines for ophthalmology and oncology indications.
With our investigational tissue factor therapeutics, we are pursuing promising opportunities to modify grievous diseases in ophthalmology, including wet age-related macular degeneration (AMD).
While tissue factor (TF) overexpression itself is not oncogenic, it facilitates key processes that lead to the development and progression of tumors. We have partnered our oncology program with Exelixis.